| 摘要 |
<P>PROBLEM TO BE SOLVED: To use a therapeutic agent which targets heat shock protein (hsp) 27 in vivo, and to provide treatment to an individual, particularly a human individual suffering from prostate cancer and other cancers that overexpress the hsp 27. <P>SOLUTION: The therapeutic agent, for example hsp27 mRNA, for example an antisense oligonucleotide or RNA interference (RNAi) nucleotide inhibitor with sequence specificity for the human hsp27 mRNA is administered to an individual suffering from the prostate cancer or some other cancer expressing elevated levels of the hsp27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in a dosage unit form. A preferred dosage unit form is an injectable dosage unit form. <P>COPYRIGHT: (C)2010,JPO&INPIT |
